Literature DB >> 3348166

Dendritic/Langerhans cells and prognosis in patients with papillary thyroid carcinomas. Immunocytochemical study of 106 thyroid neoplasms correlated to follow-up data.

S Schröder1, W Schwarz, W Rehpenning, T Löning, W Böcker.   

Abstract

Paraffin sections of 106 primary thyroid carcinomas were the subject of an immunocytochemical study to determine the density of infiltrates of S-100 protein-positive dendritic/Langerhans cells (LC), lysozyme-positive histiocytes, and LCA-positive lymphocytes. Evidence of dense infiltrates of LCs was found only in the majority of papillary thyroid carcinomas (PCs). The determination of the quantity of LCs proved to be a highly effective means of assessing the prognosis of these tumors. Irrespective of other morphologic and clinical features, no single instance of death resulting from cancer occurred among 23 PCs with dense LC infiltrates (including 6 tumors of stage pT4), while 9 of 53 (17%) of the remaining patients ultimately died from thyroid cancer. On the other hand, the degree of histiocytic and lymphocytic infiltrations was not associated with a distinct biologic behavior neither among PC nor among the remaining thyroid carcinomas. These findings suggest that LCs may play an important role in the immunologic defense mechanisms of the host against the tumor only in the papillary type of thyroid cancer.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3348166     DOI: 10.1093/ajcp/89.3.295

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  28 in total

1.  Warthin-like tumor of the thyroid a case report.

Authors:  E Sarkady; Z Sápi; V Tóth; S Kiss
Journal:  Pathol Oncol Res       Date:  1999       Impact factor: 3.201

Review 2.  Chemokines and dendritic cell traffic.

Authors:  S Sozzani; P Allavena; A Vecchi; A Mantovani
Journal:  J Clin Immunol       Date:  2000-05       Impact factor: 8.317

3.  Papillary carcinoma of the thyroid: hepatocyte growth factor (HGF) stimulates tumor cells to release chemokines active in recruiting dendritic cells.

Authors:  S Scarpino; A Stoppacciaro; F Ballerini; M Marchesi; M Prat; M C Stella; S Sozzani; P Allavena; A Mantovani; L P Ruco
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

4.  Leu-M 1 immunoreactivity in papillary carcinomas of the thyroid gland; microcarcinoma, encapsulated, conventional and diffuse sclerosing subtypes.

Authors:  M Alejo; G Peiro; E Oliva; X Matias-Guiu
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

5.  Diffuse sclerosing variant of papillary thyroid carcinoma. S-100 protein immunocytochemistry and prognosis.

Authors:  S Schröder; V Bay; K Dumke; B Kremens; H W Müller-Gärtner; W Böcker; H Kastendieck
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1990

6.  Prognostic significance of Leu-M1 immunostaining in papillary carcinomas of the thyroid gland.

Authors:  S Schröder; W Schwarz; W Rehpenning; T Löning; W Böcker
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1987

Review 7.  The utility of some modern techniques in understanding thyroid pathology.

Authors:  Virginia A LiVoisi
Journal:  Endocr Pathol       Date:  1990-06       Impact factor: 3.943

8.  Leu-M1 immunoreactivity and prognosis in medullary carcinomas of the thyroid gland.

Authors:  S Schröder; W Schwarz; W Rehpenning; H Dralle; V Bay; W Böcker
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

9.  S-100 protein+ dendritic cells and CD34+ dendritic interstitial cells in thyroid lesions.

Authors:  Anna Batistatou; Vassiliki Zolota; Chrisoula D Scopa
Journal:  Endocr Pathol       Date:  2002       Impact factor: 3.943

10.  Distribution of S-100 protein-positive dendritic cells and expression of HLA-DR antigen in transitional cell carcinoma of the urinary bladder in relation to tumour progression and prognosis.

Authors:  K Inoue; M Furihata; Y Ohtsuki; Y Fujita
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.